Amphista Therapeutics Expands Research Team by Appointing Martin O’Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry

Read full release

Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Read full release